House to vote on SGR bill with ESRD provisions

The U.S. House of Representatives is expected to vote on Thursday on a (see BioCentury Extra, Feb. 22, 2013).

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) jumped $2.45 (17%) to $16.54 on Wednesday. Stifel's Stephen Willey said the potential delay for adding oral drugs to the bundle would "remove a significant overhang that has been one of the centerpieces to the bearish arguments around the longer-term commercial opportunity" of Keryx's Zerenex ferric citrate. The product is under FDA review with a June 7 PDUFA date to treat hyperphosphatemia in chronic kidney disease (CKD) patients. ...